Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Figure 3

Event-free survival (EFS) according to patient group. The Kaplan-Meier plot of the imatinib arm of the International Randomized Study of Interferon and STI571 (IRIS) trial for frontline patients with chronic myeloid leukemia is also shown, to illustrate that biphasic responders do approximately as well as patients receiving frontline imatinib treatment.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us